16 December 2015 - In draft guidance issued on Wednesday, NICE said using Opdivo in non-small cell lung cancer after chemotherapy did not represent a cost-effective use of resources.

For more details, go to: http://www.reuters.com/article/us-bristol-myers-cancer-britain-idUSKBN0TZ00320151216